35+ years of innovation Driving creative thinking
Pioneering subcutaneous infusion therapy for over three decades, putting patients first in everything we design.
Our story,
milestone by milestone.
From our founding in 1991 to today, every innovation has been driven by a singular focus: making subcutaneous infusion simpler, safer, and better for patients everywhere.
Founded
EMED Technologies is established as a hybrid patient-centric organization and contract manufacturer, with a founding vision to improve the lives of patients receiving subcutaneous therapy.
Nipro partnership
Technology transfer agreement with Nipro Corporation for Huber needle set manufacturing. EMED's first major manufacturing partnership.
Kimberly-Clark
Manufacturing contract established with Kimberly-Clark, expanding EMED's contract manufacturing capabilities into a global market.
3M & Arrow
Manufacturing contracts signed with 3M and Arrow (a Teleflex Company), cementing EMED as a trusted contract manufacturer for leading medical device companies.
CSL Behring
Collaborative agreement with CSL Behring results in the development of the first multi-needle set specifically designed for subcutaneous immunoglobulin therapy.
VersaRate® ↳breakthrough
First patent and 510(k) clearance for VersaRate®, a first-of-its-kind variable flow rate controller giving patients unprecedented independence and comfort during infusion.
_edited.png)
SAF-Q®
Patent granted for SAF-Q®, the world's first dedicated safety needle set for SCIg therapy, designed to protect patients and caregivers during subcutaneous infusion.
SCIg60® system ↳FDA approved
First mechanical syringe pump system to receive 510(k) clearance for SCIg therapy. The FDA assigned an entirely new pump category code, recognizing the uniqueness of the SCIg60® system for Hizentra.
SCIg60®, expanded indications
First comprehensive validation of expanded SCIg indications through a joint regulatory submission with Takeda and Gammagard Liquid, opening new therapeutic possibilities for patients.
OPTFlow® ↳industry first
OPTFlow® launches as the industry's first needle set combining the highest flow rate with the lowest penetration force in the SCIg market, a breakthrough in patient comfort.
R&D expansion
Continued investment in R&D partnerships with global pharmaceutical leaders, driving the next generation of subcutaneous infusion systems and drug delivery technologies.
Global growth
EMED expands its global reach, deepening partnerships across North America, Europe, and Asia as demand for subcutaneous therapy continues to grow worldwide.
The future
Building on 35+ years of innovation, EMED continues to push the boundaries of what's possible in drug delivery, always with the patient at the centre of every decision.
Since 1991
we are
EMED Technologies.
Three decades of patient-centered innovation.
Every milestone, every breakthrough, for them.